1,721,100 research outputs found
308 nm monochromatic excimer light in the treatment of psoriasis
No full textBackground: Various reports showed the efficacy of Narrow Band UVB (311-313 nm) and excimer laser (308 nm) in the treatment of psoriasis. Objective: To prove the efficacy of light produced by xenon-cloride excimer at 308 nm (Monochromatic Excimer Light, MEL) in the treatment of stable forms of localized plaque psoriasis. Patients and methods: This study was an open trial with 152 patients affected with stable mild to moderate plaque psoriasis (PASI score between 4 and 12) were treated with a weekly session of MEL A total number of 6-16 sessions was performed with a dose increase according to patient phototype and response. Results: 152 patients were enrolled in the study and 149 completed the protocol. Patients were followed up every two weeks, 57 patients for one-year and 92 patients for 6 months. After 4 months there was complete remission in 87 patients, partial remission in 37 and moderate improvement in 25 patients. Conclusions: These preliminary results suggest that MEL can be considered as a valid option for treatment of selected forms of localized plaque psoriasis
Different monochromatic excimer light (308nm) in chronic skin diseases
No full textBackground: Ultraviolet radiation has been used for curative purposes in dermatologic conditions, especially in the last 30 years.
Objectives: We analyzed the efficacy of monochromatic excimer light in psoriasis, palmoplantar pustulosis, vitiligo, mycosis fungoides and alopecia areata, and to examine potential new indications.
Methods: Two hundred seventy-nine patients with common and persistent skin diseases were enrolled in an open prospective study: 152 patients with stable and localized plaque psoriasis, 47 with palmoplantar psoriasis, 7 with palmoplantar pustulosis, 32 with vitiligo, 11 with prurigo nodularis, 9 with mycosis fungoides stage Ia, 8 with alopecia, 5 with localized scleroderma, 5 with genital lichen sclerosus, and 3 with granuloma annulare. The 308 nm excimer light was used at a power density of 48 mW/cm(2). An average of 12 sessions (range, 6-18), one session per week, was performed and yielded a total dose range of 4-12.5 J/cm(2). Clinical response was assessed using photos, biopsies, and specific clinical scores. Patients were monitorized for 6 and 12 months for psoriasis, 12 months for mycosis fungoides, and 4 months for the remaining conditions.
Results: We observed complete remission in more than 50% of patients with plaque psoriasis and palmoplantar dermatoses, respectively, complete remission in all patients affected by mycosis fungoides, excellent repigmentation in one third of vitiligo patients, hair regrowth in three patients with alopecia areata, an overall improvement in prurigo nodularis, a partial remission in patients affected by localized scleroderma, and a complete remission in most of the patients with genital lichen sclerosus and granuloma annulare.
Conclusions: Our study confirms the use of monochromatic excimer light as a valid choice for the treatment of psoriasis, vitiligo, and mycosis fungoides; we also observed and report for the first time that monochromatic excimer light produces a therapeutic response in prurigo nodularis, localized scleroderma, genital lichen sclerosus, and granuloma annular
Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab.
Full text linkN/
An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis
No full textIntroduction: Prurigo nodularis is a distressing condition characterized by the presence of multiple nodules associated with intense pruritus. Objective: To assess the clinical efficacy and safety of betamethasone valerate 0.1% tape and a moisturizing itch-relief cream in prurigo nodularis. Methods: Twelve patients were enrolled in this pilot comparison of betamethasone valerate 0.1% tape versus a moisturizing itch-relief cream containing feverfew. The study period was 4 weeks. Clinical evaluation was performed weekly. Results: Eleven subjects completed the 4 weeks of therapy. The mean visual analogue scale (VAS) for pruritus at baseline was 8.75 for both sides of the body. The side treated with betamethasone valerate 0.1% tape showed a higher clinical response (VAS score at week 4: 3.9; p < 0.005) compared with the side treated with moisturizing itchrelief cream (VAS score at week 4: 5.6; p < 0.005). Conclusion: Both treatments were effective. However, the occlusive dressing enhanced the efficacy of the treatment, preventing scratching
Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis-fungoides
No full textBackground: Various reports have recently shown the efficacy of narrowband ultraviolet (UV) B phototherapy at 311 nm in the treatment of early stage mycosis fungoides (MF).
Objectives: To examine the effectiveness and tolerability of monochromatic excimer light (MEL) at 308 nm as a first treatment for early stage MF (stage IA).
Methods: Ten lesions from five patients with a clinical and histological diagnosis of MF were treated with repeated applications of MEL until complete remission was achieved or up to a maximum of 10 applications, with a cumulative dose of 308 nm UVB of between 6 and 12 J cm(-2). All patients were observed every 2 weeks for 2 months, with a 1-year follow-up. Results At present, all patients are in complete remission, with no side-effects.
Conclusions: Based on these results, MEL can be considered a useful tool in the treatment of early stage M
Monocromatic excimer Light treatment of psoriasis
No full textB a c k g round: Various reports showed the efficacy of Narrow Band UVB (311-313
nm) and excimer laser (308 nm) in the treatment of psoriasis.
Objective: To prove the efficacy of light produced by xenon-cloride excimer at 308
nm (Monochromatic Excimer Light, MEL) in the treatment of stable forms of
localized plaque psoriasis.
Patients and methods: This study was an open trial with 152 patients affected with
stable mild to moderate plaque psoriasis (PASI score between 4 and 12) were
t reated with a weekly session of MEL A total number of 6-16 sessions was
p e rformed with a dose increase according to patient phototype and re s p o n s e .
Results: 152 patients were enrolled in the study and 149 completed the pro t o c o l .
Patients were followed up every two weeks, 57 patients for one-year and 92 patients
for 6 months. After 4 months there was complete remission in 87 patients, partial
remission in 37 and moderate improvement in 25 patients.
Conclusions: These pre l i m i n a ry results suggest that MEL can be considered as a
valid option for treatment of selected forms of localized plaque psoriasis
Monochromatic excimer light in the treatment of early stage mycosis fungoides: A two year experience
No full textAn occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis
No full textIntroduction: Prurigo nodularis is a distressing condition characterized by the presence of multiple nodules associated with intense pruritus.
Objective: To assess the clinical efficacy and safety of betamethasone valerate 0.1% tape and a moisturizing itch-relief cream in prurigo nodularis.
Methods: Twelve patients were enrolled in this pilot comparison of betamethasone valerate 0.1% tape versus a moisturizing itch-relief cream containing feverfew. The study period was 4 weeks. Clinical evaluation was performed weekly.
Results: Eleven subjects completed the 4 weeks of therapy. The mean visual analogue scale (VAS) for pruritus at baseline was 8.75 for both sides of the body. The side treated with betamethasone valerate 0.1% tape showed a higher clinical response (VAS score at week 4: 3.9; p < 0.005) compared with the side treated with moisturizing itch-relief cream (VAS score at week 4: 5.6; p < 0.005).
Conclusion: Both treatments were effective. However, the occlusive dressing enhanced the efficacy of the treatment, preventing scratchin
Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study
No full textBackground data: Narrow band ultraviolet B (UVB) is an effective and safe option for the treatment of vitiligo. However, a complete and long-lasting repigmention of vitiligo patches is difficult to achieve. Combined treatments with novel sources of phototherapy and topical agents represent possible new strategies.
Objective: The purpose of this study was to compare the efficacy of combined tacrolimus and 308-nm excimer light (MEL) vs 308-nm MEL monotherapy in treating vitiligo in a controlled study.
Methods: Fifty-three patients affected by vitiligo were enrolled in this open prospective study. Patients were divided into three groups: Group I included 20 patients treated with MEL 308 nm twice weekly and oral vitamin E; Group II included 20 patients treated with MEL 308 nm twice weekly combined with 0.1% tacrolimus once a day and oral vitamin E; and Group III included 13 patients treated only with oral vitamin E. Efficacy was assessed at the end of 12 weeks based on the percentage of repigmentation.
Results: Fifty-two patients completed 12 weeks of treatment. Group I (MEL + vitamin E) showed a moderate repigmentation in 35% of patients, good repigmentation in 30%, excellent repigmentation in 25%, and poor repigmentation in 10%; Group II (MEL + tacrolimus 0.1%+ vitamin E) presented moderate repigmentation in 25% of patients, good repigmentation in 40%, excellent repigmentation in 30%, and poor repigmentation in 5%; Group III (vitamin E) showed moderate repigmentation in 16% and 84% did not show signs of repigmentation.
Conclusions: Our results demonstrate that the combination treatment of 0.1% tacrolimus ointment plus 308-nm MEL and 308-nm MEL monotherapy are effective, safe, and well tolerated for the treatment of vitiligo compared to treatment with vitamin E. Furthermore, this study suggests that an association with topical immunomodulators could enhance the clinical response in vitiligo, especially in more resistant anatomical site
- …
